Generate a tailored SOP for Dr. Ranjit Bindra. Improve your application with a focused, well-structured draft.
Ranjit Bindra is a physician-scientist at Yale School of Medicine and Co-Director of the Yale Brain Tumor Center at Smilow Cancer Hospital. His laboratory focuses on the DNA repair mechanisms in gliomas and the development of innovative, biomarker-driven clinical trials targeting these tumors. His groundbreaking research has identified the profound DNA repair defects in IDH1/2-mutant tumors, which increase sensitivity to PARP inhibitors. Bindra's work has received significant international recognition, highlighting its major clinical implications. He is actively involved in multiple clinical trials, including a notable NCI-sponsored Phase II trial testing the PARP inhibitor olaparib for adult patients with IDH1/2-mutant solid tumors. Dr. Bindra co-founded Cybrexa Therapeutics, aimed at creating novel small molecule DNA repair inhibitors tailored for the tumor microenvironment. His academic journey includes an MD and PhD from Yale, and extensive training in radiation oncology at Memorial Sloan-Kettering Cancer Center.
Yale School of Medicine • New Haven, CT
Oversees translational research initiatives at the Yale School of Medicine.
Chênevert Family Brain Tumor Center • New Haven, CT
Leads the Chênevert Family Brain Tumor Center at Yale in clinical and research endeavors.
Administered via the Graduate School of Arts and Sciences (GSAS). GRE General is optional for PhD.